MaaT Pharma secures a €37.5 million loan from the EIB to further developing cancer treatments.
MaaT Pharma, a clinical-stage biotechnology company based in Lyon, France, has secured a significant investment of €37.5 million in the form of a loan from the European Investment Bank (EIB). This funding will help the company advance its late-stage hemato-oncology programs, including the development of MaaT033, which is currently in a Phase 2b trial for allogeneic stem cell transplant patients.
The EIB loan is a further foundation for MaaT Pharma's growth, strengthening its financial position and supporting its mission to bring the first microbiome-based therapy to market in Europe. The company aims to achieve this milestone with Xervyteg (MaaT013), a microbiome-based therapy currently under review by the European Medicines Agency (EMA) for treating acute Graft-versus-Host Disease (aGvHD).
MaaT Pharma completed enrollment for the Phase 3 ARES trial of Xervyteg in October 2024 and submitted the Marketing Authorization Application (MAA) to the EMA in June 2025. Xervyteg uses proprietary pooling and co-cultivation technologies to produce a high-diversity microbiome product aimed at enhancing immune response and patient survival.
In addition to Xervyteg, MaaT Pharma has also secured an exclusive distribution agreement with Clinigen for Europe to commercialize Xervyteg if approved. The company emphasizes that, if approved, Xervyteg could become the first microbiome-based therapeutic in oncology available on the European market, representing a significant commercial and scientific milestone.
Parallel to the development of Xervyteg, MaaT Pharma is also advancing MaaT033, another microbiome ecosystem therapy aimed at allogeneic stem cell transplant patients. The company's recent announcements include a partnership financing with Clinigen and debt financing with the EIB, demonstrating its commitment to fund its plans and development programs while preserving shareholder value.
MaaT Pharma continues to develop innovative microbiome-driven immunomodulators to extend cancer patient survival, supported by proprietary pooling technologies and a committed R&D team. With the EIB loan, the company is one step closer to making these groundbreaking therapies available to patients across Europe.
[1] MaaT Pharma Press Release. (2025, July). MaaT Pharma secures €37.5 million loan from the European Investment Bank (EIB) to advance late-stage hemato-oncology programs. [online] Available at: https://www.maatpharma.com/news/maat-pharma-secures-37-5-million-loan-from-the-european-investment-bank-eib-to-advance-late-stage-hemato-oncology-programs/
[2] Clinigen Press Release. (2024, October). MaaT Pharma completes enrollment for the ARES trial of Xervyteg in October 2024. [online] Available at: https://www.clinigengroup.com/news/maat-pharma-completes-enrollment-for-the-ares-trial-of-xervyteg-in-october-2024/
[3] EMA Press Release. (2025, June). MaaT Pharma submits Marketing Authorization Application (MAA) to the EMA for Xervyteg(MaaT013) in June 2025. [online] Available at: https://www.ema.europa.eu/en/news/maat-pharma-submits-marketing-authorization-application-mma-ema-xervytegmaat013-june-2025
[4] MaaT Pharma Press Release. (2025, July). MaaT Pharma's financial strategy: non-dilutive and dilutive sources. [online] Available at: https://www.maatpharma.com/news/maat-pharmas-financial-strategy-non-dilutive-and-dilutive-sources/
Science continues to play a crucial role in MaaT Pharma's mission, as they develop microbiome-based therapies to address medical-conditions like cancer. The company's latest funding from the European Investment Bank (EIB) will aid in the advancement of these health-and-wellness focused projects, such as the Phase 2b trial for MaaT033 and the potential approval of Xervyteg (MaaT013) for treating aGvHD, representing a significant scientific milestone in oncology.
